NEW YORK (GenomeWeb News) - UK cancer detection firm Oncimmune will develop a diagnostic test for lung cancer using Proteome Sciences’ patents covering the Annexin I and Annexin 2 proteins under a non-exclusive licensing agreement announced by the two firms this week.
 
A test is expected to hit the market during the first half of the year, Proteome Sciences said in a statement. It will receive royalty payments from product sales under the agreement.
 
Further terms of the deal were not disclosed.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.